Intellect Neurosciences Inc. (fka ILNS)

[montanus]

A perspective:

NEW YORK, Nov. 28, 2012

Intellect Neurosciences Announces New Findings Supporting its Patented ANTISENILIN Platform Technology for the Treatment of Alzheimer's Disease

https://globenewswire.com/news-release/2012/11/28/507983/10013867/en/Intellect-Neurosciences-Announces-New-Findings-Supporting-its-Patented-ANTISENILIN-Platform-Technology-for-the-Treatment-of-Alzheimer-s-Disease.html


2014-09-12 <maximum_age>
80 Years
90 Years

https://clinicaltrials.gov/archive/NCT01821118/2014_08_12/changes

So, I guess ponezumab is pretty save!

Mouse trial (Brain. 2015 Oct 22. pii: awv313. [Epub ahead of print])

Passive immunotherapy targeting amyloid-ß reduces cerebral amyloid angiopathy and improves vascular reactivity.
Bales KR1, O'Neill SM2, Pozdnyakov N2, Pan F2, Caouette D2, Pi Y2, Wood KM2, Volfson D2, Cirrito JR3, Han BH4, Johnson AW4, Zipfel GJ5, Samad TA1.
Author information
Abstract
Prominent cerebral amyloid angiopathy is often observed in the brains of elderly individuals and is almost universally found in patients with Alzheimer's disease. Cerebral amyloid angiopathy is characterized by accumulation of the shorter amyloid-ß isoform(s) (predominantly amyloid-ß40) in the walls of leptomeningeal and cortical arterioles and is likely a contributory factor to vascular dysfunction leading to stroke and dementia in the elderly. We used transgenic mice with prominent cerebral amyloid angiopathy to investigate the ability of ponezumab, an anti-amyloid-ß40 selective antibody, to attenuate amyloid-ß accrual in cerebral vessels and to acutely restore vascular reactivity. Chronic administration of ponezumab to transgenic mice led to a significant reduction in amyloid and amyloid-ß accumulation both in leptomeningeal and brain vessels when measured by intravital multiphoton imaging and immunohistochemistry. By enriching for cerebral vascular elements, we also measured a significant reduction in the levels of soluble amyloid-ß biochemically. We hypothesized that the reduction in vascular amyloid-ß40 after ponezumab administration may reflect the ability of ponezumab to mobilize an interstitial fluid pool of amyloid-ß40 in brain. Acutely, ponezumab triggered a significant and transient increase in interstitial fluid amyloid-ß40 levels in old plaque-bearing transgenic mice but not in young animals. We also measured a beneficial effect on vascular reactivity following acute administration of ponezumab, even in vessels where there was a severe cerebral amyloid angiopathy burden. Taken together, the beneficial effects ponezumab administration has on reducing the rate of cerebral amyloid angiopathy deposition and restoring cerebral vascular health favours a mechanism that involves rapid removal and/or neutralization of amyloid-ß species that may otherwise be detrimental to normal vessel function.

http://www.ncbi.nlm.nih.gov/pubmed/26493635

PONEZUMAB TRIAL COMPLETED 2016-02-05
Changes to NCT01821118 on 2016_02_05
Active, not recruiting
Completed

https://clinicaltrials.gov/archive/NCT01821118/2016_02_05/changes



Statement of Ownership (sc 13g)
Date : 02/05/2016 @ 12:43PM

http://ir.stockpr.com/intellectns/sec-filings#

???


02/16/16 SC 13G/A
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions

http://ir.stockpr.com/intellectns/sec-filings#